The attack leaves a trace in the blood. T1D is autoimmune: T cells kill the insulin-making beta cells over months to years, and by the time a child is thirsty and losing weight, most of those cells are gone. Long before that, the blood carries islet autoantibodies. Two or more persistent ones in childhood mean the attack has begun, and only the timing of diabetes is still open 1.
Teplizumab is the first drug that changes the clock. It's an antibody that quiets the T cells doing the killing. Given as one 14-day course at the pre-diabetic Stage 2, it pushed the median time to clinical diabetes from 24.4 to 48.4 months 2. Longer follow-up widened the gap to about a 32-month median delay 3.
Screening does most of the work on its own. About one in four US kids first learns they have T1D during a dangerous crisis called DKA. Kids found through screening arrive that way roughly one time in twenty instead 4. The diagnosis still comes, but as a clinic appointment instead of an ambulance.
If a relative has T1D, request the free screen first. The drug decision comes later, and only for a few.
The teplizumab course itself is 14 consecutive weekdays of infusions at a specialty center, about two hours each, after baseline labs 5. One course only; re-treatment isn't approved.
A positive screen lands hard, then quiets. Parental distress rises in the first weeks and settles over months; a year out it typically sits below the worry families carried when they didn't know 6. Day to day the child plays soccer, eats birthday cake, and sees the endocrinologist twice a year. If the family chooses teplizumab, the two-week course is the only visible event, and eighteen months on, when untreated peers were tipping into diabetes, this child is still Stage 2 2. When Stage 3 finally arrives, the supplies are already on the shelf.
Screening is free through TrialNet; teplizumab lists near $194,000 a course, usually covered with prior authorization at Stage 2 8.
The fine print — when to skip it, and what people get wrong
"Teplizumab cures T1D." No. It delays onset by a median of a few years; on long follow-up most treated patients develop diabetes anyway 3. Delay is not prevention.
"Screening is only for families with T1D." Relatives are the highest-yield group, but 85–90% of new cases have no family history, which is why general-population pilots exist 7.
Teplizumab is a real immunosuppressant: not in pregnancy, not during active infection, not below age 8 5. Screening carries no such catch, and its DKA benefit applies at any age.
- 1Ziegler AG, Rewers M, Simell O et al. (2013). Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. link
- 2Herold KC, Bundy BN, Long SA et al. (2019). An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. New England Journal of Medicine. link
- 3Sims EK, Bundy BN, Stier K et al. (2021). Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Science Translational Medicine. link
- 4Hummel S, Carl J, Friedl N et al. (2023). Children diagnosed with presymptomatic type 1 diabetes through public health screening have a low rate of diabetic ketoacidosis at clinical onset. Diabetologia. link
- 5FDA (2022). FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes. link
- 6Hummel S, Pflüger M, Kreichauf S et al. (2017). Psychological impact of childhood islet autoantibody testing in families participating in the Fr1da study. Diabetic Medicine. link
- 7Ziegler AG, Kick K, Bonifacio E et al. (2020). Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. JAMA. link
- 8ICER (2023). Teplizumab for the Prevention of Type 1 Diabetes: Effectiveness and Value — Final Evidence Report. link
დაკავშირებული სახელმძღვანელოში (4)
- — Type 1 diabetes and celiac cluster in the same families. A celiac diagnosis is a nudge to know your own T1D risk.
- — For someone with autoantibodies flagged by T1D screening, a CGM is an early-warning tool for the onset of diabetes.
- — For a first-degree relative of someone with type 1 diabetes, a free antibody screen catches the attack years before symptoms.
- — This is type 1 — an autoimmune attack you can screen for and delay — not type 2, a different disease with a different playbook.
Teplizumab and T1D Screening
TN-10 RCT (Herold et al. 2019) showed a median 24-month delay in time to clinical T1D from a single 14-day teplizumab course in Stage 2 relatives; extended follow-up (Sims et al. 2021) widened the median delay to ~32.5 months with 50% vs 22% remaining diabetes-free. Years of normal pancreatic function and reduced DKA at onset translate to less cumulative hyperglycemia and lower long-term microvascular complication risk.
Screening is a single blood draw (capillary or venous) with mailed at-home kits available through TrialNet — trivial. Treatment requires 14 consecutive weekday IV infusions (~1.5–2.5 hours each) at a specialty infusion center, plus 6-monthly metabolic monitoring (OGTT, HbA1c) afterward — a defined burden over weeks, not a daily ongoing one.
Single pivotal RCT (TN-10, n=76, Herold et al. 2019) with consistent extended follow-up (Sims et al. 2021); independent confirmation of β-cell preservation in newly-diagnosed T1D (PROTECT phase 3, Ramos et al. 2023); FDA-approved 2022; ADA Standards of Care 2024 endorse the staging-and-screening framework. Sample size and population diversity limit it below a multi-trial 5.
Through structured monitoring after a positive screen, DKA at clinical T1D diagnosis falls from ~20–30% to ~3–5% (Hummel et al. 2023, Fr1da cohort) — the felt difference between a routine endocrinology visit and an ICU admission. Drug-side short-term effect modest: transient cytokine-release symptoms and lymphopenia balance against earlier metabolic stability.
Screening through TrialNet is free; the teplizumab course carries a US list price of $193,900 (ICER 2023). Most US insurers cover with prior authorization for Stage 2 criteria, but out-of-pocket varies from $0 (Medicaid, low-deductible plans) to several thousand on high-deductible plans, and uninsured cash exposure is prohibitive.
Mixed direction: initial parental anxiety after a positive autoantibody result is real (Johnson et al. 2011 TEDDY, Hummel et al. 2017 Fr1da), but adapts within months; structured monitoring replaces vague background worry common in T1D-relative families with a known trajectory. Net small positive in families with prior T1D awareness; smaller or neutral effect in general-population screen-positives.